Alvine Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing therapeutics for autoimmune/gastrointestinal diseases. Alvine's lead product candidate, ALV003, is a combination protease engineered to digest gluten. It is being developed to treat patients with celiac disease. There is no therapy available for treating celiac disease other than complete, life-long avoidance of gluten, a very common food ingredient. Even highly motivated patients who diligently strive to exclude all gluten from their diets may continue to have ongoing damage from celiac disease due to inadvertently ingesting small amounts of gluten. There is a high unmet medical need for celiac disease therapies.     NEWS   Alvine Pharmaceuticals to Present at Lazard Healthcare Conference in New York SAN CARLOS, Calif. – November 11, 2009 - Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced President and Chief Executive Officer Abhay Joshi will present at the Lazard Capital Markets Sixth Annual Healthcare Conference at 11:30 a.m. ET on Wednesday, November 18.  The conference will be held at The St. Regis Hotel in New York City. Read more   Alvine Pharmaceuticals Raises $21.5 Million Series A Extension SAN CARLOS, Calif. – September 15, 2009 - Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced the closing of a $21.5 million extension of its Series A financing.  New investor Panorama Capital led the financing round, joining founding investors InterWest Partners, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures. Read more Alvine Initiates Enrollment in Phase 2a Clinical Trial of ALV003 for Use in the Treatment of Celiac Disease SAN CARLOS, Calif., August 25, 2009 - Alvine Pharmaceuticals, Inc. today announced that patient enrollment has begun in a Phase 2a, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ALV003 for use in the treatment of celiac disease. Read more. Alvine Pharmaceuticals Appoints Dr. Daniel C. Adelman, M.D., as Senior Vice President and Chief Medical Officer SAN CARLOS, Calif., March 19, 2009 - Alvine Pharmaceuticals, Inc. today announced the appointment of Dr. Daniel C. Adelman as Senior Vice President, Development and Chief Medical Officer (CMO). “I am extremely pleased to welcome Dan to Alvine’s management team.  His drug development expertise in biopharmaceuticals will be of great value to Alvine as the company advances its lead compound, ALV003 into Phase 2 clinical trials this year,” said Dr. Abhay Joshi, Alvine’s President and Chief Executive Officer.  Read more. Additional information about Alvine's clinical trials can be found here.